DBV Technologies Investor Relations Material
Latest events
Study Update
DBV Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from DBV Technologies S.A.
Access all reports
DBV Technologies S.A. is a French biopharmaceutical company focused on developing therapies for food allergies using its proprietary epicutaneous immunotherapy (EPIT) technology platform. The company's lead product candidate is designed to treat peanut allergies by delivering allergens through the skin to desensitize patients while minimizing the risk of severe allergic reactions. DBV's non-invasive approach aims to provide safe and effective treatments for patients with food allergies, addressing a significant unmet need in allergy management. The company is headquartered in Montrouge, France, and its shares are listed on Euronext Paris and the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
DBV
Country
🇫🇷 France